|
1
|
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
|
J Allergy Clin Immunol
|
2006
|
6.64
|
|
2
|
Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel.
|
J Allergy Clin Immunol
|
2010
|
5.55
|
|
3
|
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
|
N Engl J Med
|
2008
|
4.55
|
|
4
|
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report.
|
J Allergy Clin Immunol
|
2010
|
2.98
|
|
5
|
Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group.
|
Ann Allergy Asthma Immunol
|
2006
|
2.85
|
|
6
|
Self-injectable epinephrine for first-aid management of anaphylaxis.
|
Pediatrics
|
2007
|
2.78
|
|
7
|
Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report.
|
J Allergy Clin Immunol
|
2006
|
2.00
|
|
8
|
First do no harm: managing antihistamine impairment in patients with allergic rhinitis.
|
J Allergy Clin Immunol
|
2003
|
1.55
|
|
9
|
Allergen-specific oral immunotherapy for peanut allergy.
|
Cochrane Database Syst Rev
|
2012
|
1.51
|
|
10
|
Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology.
|
Ann Allergy Asthma Immunol
|
2006
|
1.47
|
|
11
|
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.
|
J Allergy Clin Immunol
|
2009
|
1.38
|
|
12
|
Glucocorticoids for the treatment of anaphylaxis.
|
Evid Based Child Health
|
2013
|
1.38
|
|
13
|
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
|
J Allergy Clin Immunol
|
2007
|
1.32
|
|
14
|
Anaphylaxis epidemic: fact or fiction?
|
J Allergy Clin Immunol
|
2008
|
1.23
|
|
15
|
Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report.
|
Nutr Res
|
2011
|
1.14
|
|
16
|
Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.
|
J Allergy Clin Immunol
|
2012
|
1.14
|
|
17
|
Histamine receptors are hot in immunopharmacology.
|
Eur J Pharmacol
|
2006
|
1.13
|
|
18
|
Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics.
|
AAPS PharmSciTech
|
2006
|
1.12
|
|
19
|
Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock.
|
Cochrane Database Syst Rev
|
2008
|
1.11
|
|
20
|
Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA).
|
Allergy
|
2003
|
1.08
|
|
21
|
Immune responses to mosquito saliva in 14 individuals with acute systemic allergic reactions to mosquito bites.
|
J Allergy Clin Immunol
|
2004
|
1.07
|
|
22
|
Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma.
|
J Allergy Clin Immunol
|
2009
|
1.06
|
|
23
|
Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization.
|
World Allergy Organ J
|
2008
|
1.04
|
|
24
|
Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop.
|
FASEB J
|
2003
|
1.04
|
|
25
|
Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort.
|
Curr Respir Care Rep
|
2012
|
1.01
|
|
26
|
Mosquito allergy: immune mechanisms and recombinant salivary allergens.
|
Int Arch Allergy Immunol
|
2004
|
0.99
|
|
27
|
Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma.
|
J Allergy Clin Immunol
|
2007
|
0.98
|
|
28
|
Emergency treatment of anaphylaxis.
|
BMJ
|
2008
|
0.98
|
|
29
|
IgE modulates neutrophil survival in asthma: role of mitochondrial pathway.
|
J Immunol
|
2007
|
0.97
|
|
30
|
Epinephrine and its use in anaphylaxis: current issues.
|
Curr Opin Allergy Clin Immunol
|
2010
|
0.97
|
|
31
|
Mosquito saliva-specific IgE and IgG antibodies in 1059 blood donors.
|
J Allergy Clin Immunol
|
2002
|
0.95
|
|
32
|
Advances in mosquito allergy.
|
Curr Opin Allergy Clin Immunol
|
2007
|
0.93
|
|
33
|
Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel Report.
|
Nutrition
|
2011
|
0.92
|
|
34
|
Anaphylaxis and vitamin D: a role for the sunshine hormone?
|
J Allergy Clin Immunol
|
2007
|
0.91
|
|
35
|
Evidence for natural desensitization to mosquito salivary allergens: mosquito saliva specific IgE and IgG levels in children.
|
Ann Allergy Asthma Immunol
|
2004
|
0.90
|
|
36
|
Glucocorticoids for the treatment of anaphylaxis.
|
Cochrane Database Syst Rev
|
2010
|
0.90
|
|
37
|
Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis.
|
J Allergy Clin Immunol
|
2006
|
0.90
|
|
38
|
Glucocorticoids for the treatment of anaphylaxis.
|
Cochrane Database Syst Rev
|
2012
|
0.90
|
|
39
|
Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice.
|
Am J Respir Crit Care Med
|
2007
|
0.89
|
|
40
|
Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations.
|
Ann Allergy Asthma Immunol
|
2012
|
0.89
|
|
41
|
Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community.
|
J Allergy Clin Immunol
|
2005
|
0.89
|
|
42
|
H1-antihistamines and the central nervous system.
|
Clin Allergy Immunol
|
2002
|
0.89
|
|
43
|
An electronic tongue: evaluation of the masking efficacy of sweetening and/or flavoring agents on the bitter taste of epinephrine.
|
AAPS PharmSciTech
|
2010
|
0.89
|
|
44
|
Dissolution testing of sublingual tablets: a novel in vitro method.
|
AAPS PharmSciTech
|
2011
|
0.89
|
|
45
|
Clinical outcomes and adverse effect monitoring in allergic rhinitis.
|
J Allergy Clin Immunol
|
2005
|
0.88
|
|
46
|
Regulation of the high affinity IgE receptor (Fc epsilonRI) in human neutrophils: role of seasonal allergen exposure and Th-2 cytokines.
|
PLoS One
|
2008
|
0.87
|
|
47
|
Human subjects without peanut allergy demonstrate T cell-dependent, TH2-biased, peanut-specific cytokine and chemokine responses independent of TH1 expression.
|
J Allergy Clin Immunol
|
2006
|
0.87
|
|
48
|
Inhaled corticosteroids in childhood asthma: Income differences in use.
|
Pediatr Pulmonol
|
2003
|
0.87
|
|
49
|
Human metapneumovirus elicits weak IFN-gamma memory responses compared with respiratory syncytial virus.
|
J Immunol
|
2006
|
0.86
|
|
50
|
Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock.
|
Int Arch Allergy Immunol
|
2002
|
0.86
|
|
51
|
Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability?
|
Biopharm Drug Dispos
|
2006
|
0.85
|
|
52
|
Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel report.
|
J Am Acad Dermatol
|
2011
|
0.85
|
|
53
|
Elevated antigen-driven IL-9 responses are prominent in peanut allergic humans.
|
PLoS One
|
2012
|
0.84
|
|
54
|
Drug-device combination products in the twenty-first century: epinephrine auto-injector development using human factors engineering.
|
Expert Opin Drug Deliv
|
2014
|
0.83
|
|
55
|
Systemic chemokine and chemokine receptor responses are divergent in allergic versus non-allergic humans.
|
Int Immunol
|
2002
|
0.82
|
|
56
|
Adrenaline (epinephrine) microcrystal sublingual tablet formulation: enhanced absorption in a preclinical model.
|
J Pharm Pharmacol
|
2014
|
0.82
|
|
57
|
Fast-disintegrating sublingual epinephrine tablets: effect of tablet dimensions on tablet characteristics.
|
Drug Dev Ind Pharm
|
2007
|
0.82
|
|
58
|
Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model.
|
AAPS PharmSci
|
2003
|
0.81
|
|
59
|
Relevance of H1-receptor occupancy to H1-antihistamine dosing in children.
|
J Allergy Clin Immunol
|
2007
|
0.81
|
|
60
|
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.
|
J Allergy Clin Immunol
|
2011
|
0.81
|
|
61
|
Epinephrine (adrenaline) absorption from new-generation, taste-masked sublingual tablets: a preclinical study.
|
J Allergy Clin Immunol
|
2012
|
0.80
|
|
62
|
Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis.
|
Ann Allergy Asthma Immunol
|
2009
|
0.79
|
|
63
|
Development of a drug treatment-based severity measure in childhood asthma.
|
J Asthma
|
2002
|
0.79
|
|
64
|
Comparison of asthma exacerbations in pediatric and adult patients with severe or difficult-to-treat asthma.
|
J Allergy Clin Immunol
|
2009
|
0.79
|
|
65
|
Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrine.
|
Drug Dev Ind Pharm
|
2004
|
0.79
|
|
66
|
Rapidly-disintegrating sublingual tablets of epinephrine: role of non-medicinal ingredients in formulation development.
|
Eur J Pharm Biopharm
|
2012
|
0.79
|
|
67
|
Apparent lack of response to epinephrine in anaphylaxis.
|
J Allergy Clin Immunol
|
2005
|
0.78
|
|
68
|
Long-term stability of epinephrine sublingual tablets for the potential first-aid treatment of anaphylaxis.
|
Ann Allergy Asthma Immunol
|
2013
|
0.78
|
|
69
|
Eventual full-text publication of research abstracts presented at an allergy/immunology meeting.
|
J Allergy Clin Immunol
|
2006
|
0.78
|
|
70
|
Adult asthmatics display exaggerated IFNgamma responses to human metapneumovirus and respiratory syncytial virus.
|
Biochem Cell Biol
|
2007
|
0.78
|
|
71
|
Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model.
|
AAPS J
|
2004
|
0.78
|
|
72
|
Diphenhydramine in infants.
|
Arch Pediatr Adolesc Med
|
2007
|
0.77
|
|
73
|
Concomitant chronic pulmonary diseases and their association with hospital outcomes in patients with anaphylaxis and other allergic conditions: a cohort study.
|
BMJ Open
|
2013
|
0.76
|
|
74
|
Reovirus serotypes elicit distinctive patterns of recall immunity in humans.
|
J Virol
|
2008
|
0.76
|
|
75
|
Comparision of the mosquito saliva-capture enzyme-linked immunosorbent assay and the unicap test in the diagnosis of mosquito allergy.
|
Ann Allergy Asthma Immunol
|
2007
|
0.76
|
|
76
|
Timing the transfer of responsibilities for anaphylaxis recognition and use of an epinephrine auto-injector from adults to children and teenagers: pediatric allergists' perspective.
|
Ann Allergy Asthma Immunol
|
2012
|
0.76
|
|
77
|
Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community.
|
Cochrane Database Syst Rev
|
2012
|
0.76
|
|
78
|
Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis.
|
J Allergy Clin Immunol
|
2003
|
0.76
|
|
79
|
Are plasma IL-10 levels a useful marker of human clinical tolerance in peanut allergy?
|
PLoS One
|
2010
|
0.75
|
|
80
|
Hydroxyzine- and cetirizine-loaded liposomes: effect of duration of thin film hydration, freeze-thawing, and changing buffer pH on encapsulation and stability.
|
Drug Dev Ind Pharm
|
2005
|
0.75
|
|
81
|
Immunotherapy with a ragweed vaccine.
|
N Engl J Med
|
2007
|
0.75
|
|
82
|
Early-onset cellulitis after insect bites: allergic inflammation.
|
Ann Allergy Asthma Immunol
|
2004
|
0.75
|
|
83
|
New visions for anaphylaxis: an iPAC summary and future trends.
|
Pediatr Allergy Immunol
|
2008
|
0.75
|
|
84
|
Peanut allergy: recent advances.
|
Pediatr Res
|
2003
|
0.75
|
|
85
|
Moving forward in pediatric allergy & immunology.
|
Pediatr Allergy Immunol
|
2003
|
0.75
|
|
86
|
Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study.
|
Biopharm Drug Dispos
|
2002
|
0.75
|
|
87
|
Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model.
|
Biopharm Drug Dispos
|
2004
|
0.75
|
|
88
|
rAed a 4: A New 67-kDa Aedes aegypti Mosquito Salivary Allergen for the Diagnosis of Mosquito Allergy.
|
Int Arch Allergy Immunol
|
2016
|
0.75
|
|
89
|
Simultaneous analysis of the H1-antihistamine acrivastine and the decongestant pseudoephedrine hydrochloride by high-performance liquid chromatography.
|
J Pharm Biomed Anal
|
2004
|
0.75
|
|
90
|
The allergy archives: pioneers and milestones.
|
J Allergy Clin Immunol
|
2006
|
0.75
|